Guidelines on cardiovascular risk assessment and management

Size: px
Start display at page:

Download "Guidelines on cardiovascular risk assessment and management"

Transcription

1 European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi: /eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine at the National Heart and Lung Institute, Imperial College, London, UK 2 Hammersmith Hospitals NHS Trust, London, UK KEYWORDS Atherosclerosis; Cardiovascular disease; Guidelines; Lifestyle modification; Obesity; SCORE; Treatment targets Cardiovascular disease is the major cause of premature death in most European populations. The underlying pathology is usually atherosclerosis. Cardiovascular disease is closely related to lifestyle and modifiable physiological factors, and risk factor modification has been shown to reduce cardiovascular morbidity and mortality. The current joint European Guidelines differ from previous ones in that the emphasis has moved from coronary heart disease prevention to cardiovascular disease prevention. The Systematic Coronary Risk Evaluation system is recommended to assess an individual s total cardiovascular risk. The guidelines define priorities for intervention and address lifestyle change and management of major cardiovascular risk factors to reduce cardiovascular events. Reduction of overweight and obesity is an important component in reducing cardiovascular risk. Cardiovascular disease is the major cause of death in adults in most European countries. It results in substantial disability and loss of productivity and contributes significantly to the escalating costs of health care, especially in the context of an ageing population. Cardiovascular disease accounts for 49% of all deaths in Europe and for 30% of all premature deaths (those occurring before 65 years). It is the major cause of premature death in most European populations: one in eight men and one in 17 women die from cardiovascular disease before 65 years. There are marked differences in cardiovascular disease mortality rates between countries. Trends of age and gender-standardized cardiovascular mortality from 1980 show down-sloping curves in Nordic, western, and southern Europe (except Greece) but stable or rising curves in central and eastern European countries. However, as cardiovascular disease is strongly related to age, its prevalence is rising. This, together with an improved cardiovascular disease treatment and survival rate, means that an increasing number of individuals in Europe are living with impaired cardiovascular health and are at risk of recurrent disease (re-infarction, * Corresponding author. address: d.wood@imperial.ac.uk recurrent stroke, heart failure, and sudden death). Therefore, the overall burden of cardiovascular disease is expected to increase in the coming decade. 1 The development of cardiovascular disease is strongly related to lifestyle factors such as diet, physical inactivity, and tobacco smoking. These promote adverse changes in biochemical and physiological characteristics, which in turn accelerate the development of atherosclerosis and associated thrombotic complications. It is increasingly clear that these cardiovascular risk factors interact with each other synergistically. There is now considerable evidence that lifestyle modification and risk factor management can slow the development of cardiovascular disease, both before and after the occurrence of an acute event. This evidence has been synthesized into recommendations on cardiovascular disease prevention in clinical practice, published by the Joint European Societies. 2 The Third Joint Task Force, which produced the 2003 joint European Guidelines, is a collaboration of eight groups: the European Society of Cardiology, European Society of Atherosclerosis, European Society of Hypertension, European Society of General Practice/Family Medicine, European Heart Network, International Society of Behavioural Medicine, European Association & The European Society of Cardiology All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org

2 L6 D.A. Wood for the Study of Diabetes, and the International Diabetes Federation Europe. The 2003 European Guidelines differ from previous ones in that the emphasis has moved from coronary heart disease prevention to cardiovascular disease prevention. The latest World Health Organization statistics show that in women, coronary heart disease accounted for 23% of deaths, stroke for 18%, and other cardiovascular disease for 15%. (In contrast, cancer accounted for 27% of deaths in women.) The situation for men is similar. Therefore, it is important to target all patients with atherosclerotic disease, not just those with coronary artery disease. The guidelines define priorities and thresholds for treatment and treatment targets. The top priority is patients with established atherosclerotic disease, i.e. established coronary heart disease, peripheral artery disease, and cerebrovascular atherosclerotic disease. The second priority group is asymptomatic, apparently healthy, individuals who are identified as being at high risk of developing atherosclerotic cardiovascular disease in the foreseeable future, on the basis of a clustering of risk factors. This group of high-risk individuals includes patients with diabetes. Different multi-factorial risk models have been developed to assess the risk for development of cardiovascular disease. The European Guidelines recommend the use of the SCORE (Systematic Coronary Risk Evaluation) system. 3 The SCORE risk assessment system is derived from a large data set of prospective European studies. From an individual s age, gender, smoking habit, systolic blood pressure, and total cholesterol/hdl cholesterol ratio, it provides an estimate of their total risk of developing fatal cardiovascular disease over a period of 10 years. The importance of this approach is that the absolute risk of developing cardiovascular disease depends on the presence of multiple risk factors. Addressing a single risk factor, such as blood pressure, lipids, or glucose, in isolation misses the fundamental challenge of addressing all risk factors simultaneously, in order to reduce the risk of cardiovascular disease. The third priority group is close relatives of patients with early-onset atherosclerosis and asymptomatic individuals at particularly high risk (e.g. families with familial hypercholesterolaemia or other forms of inherited dyslipidaemia). From epidemiological studies, a great deal is known about the underlying causes of atherosclerosis and its thrombotic complications. However, it is a widely held misconception that the established cardiovascular risk factors (Figure 1) only explain about half of all the cardiovascular disease in the population. The recent INTERHEART case control study 4 clearly demonstrates the overwhelming importance of these risk factors. INTERHEART assessed potentially modifiable risk associated with myocardial infarction in 52 countries from each of the major regions of the world. It involved 262 centres and over patients with an initial myocardial infarction and a similar number of healthy controls. Analysis was based on cases and controls. Figure 1 Lifestyles and characteristics associated with the risk of cardiovascular events (adapted from De Backer et al. 2 ). The study showed convincingly that the major risk factors for cardiovascular disease are apob/apoa-1 ratio, smoking, diabetes, hypertension, abdominal obesity, psychosocial factors, consumption of fruit and vegetables, alcohol, and regular exercise (Table 1). All these risk factors were significantly related (P, ) either directly or inversely to the risk of a first myocardial infarction, with the exception of alcohol, which had a weaker association (P ¼ 0.03). Daily consumption of fruits or vegetables, moderate or strenuous exercise, and consumption of alcohol three or more times a week were protective. These risk factors collectively accounted for about 90% of the population attributable risk and hence are the major causes of atherosclerosis and its complications. The same associations were found in men and women at all ages and in all regions of the world. After multivariate analysis, raised apob/apoa-1 ratio and current smoking were the two strongest risk factors. The INTERHEART study has highlighted the importance of multiplicative risk. With all nine risk factors (current or former smoking, history of diabetes or hypertension, abdominal obesity, psychosocial stress, irregular consumption of fruits and vegetables, no alcohol intake, avoidance of regular exercise, and raised plasma lipids), the odds ratio was 129 when compared with not having any of these risk factors. Substituting the odds ratios for current smoking, the extremes of abdominal obesity (top vs. lowest tertile) and apob/apoa-1 ratio (top vs. lowest quintile) increased the odds ratio for all risk factors combined to 333, i.e. the chance of having an initial myocardial infarction is 333 times that of the healthy population (Figure 2). It is important to note that several of these cardiovascular risk factors apob/apoa-1 ratio, diabetes, hypertension, abdominal obesity, diet, and physical activity are included in the definitions of the metabolic syndrome and are closely related to obesity and the distribution of fat. Lifestyle modification Lifestyle modification is the foundation of any preventive cardiology programme, and the European Guidelines address the issue of lifestyle change. The aim is to help

3 Guidelines on cardiovascular risk assessment and management L7 Table 1 Data from the INTERHEART study showing risk of acute myocardial infarction associated with risk factors in the overall population 4 Risk factor Controls (%) Cases (%) OR (99% CI) adjusted for age, sex, and smoking OR (99% CI) adjusted for all risk factors ApoB/ApoA-1 ratio (5 vs. 1) ( ) 3.25 ( ) Current smoking ( ) 2.87 ( ) Diabetes ( ) 2.37 ( ) Hypertension ( ) 1.91 ( ) Abdominal obesity (3 vs. 1) ( ) 1.62 ( ) All psychosocial 2.51 ( ) 2.67 ( ) Vegetables and fruit daily ( ) 0.70 ( ) Exercise ( ) 0.86 ( ) Alcohol intake ( ) 0.91 ( ) All combined ( ) ( ) The odds ratio of is derived by combining all risk factors, including current and former smoking vs. never smoking, top two tertiles vs. the lowest tertile of abdominal obesity, and top four quintiles vs. the lowest quintile of apob/apoa-1. Including only current smoking vs. never smoking, the top vs. the lowest tertile for abdominal obesity, and the top vs. the lowest quintile for apob/apoa-1, the odds ratio increases to (adapted with permission from Yusuf et al. 4 ). Figure 2 Risk of acute myocardial infarction associated with exposure to multiple risk factors. 4 The odds ratios are based on current vs. never smoking, top vs. lowest tertile for abdominal obesity, and top vs. lowest quintile for apob/apoa-1. (Adapted with permission from Yusuf et al. 4 ) patients with coronary heart disease or other atherosclerotic disease and healthy high-risk individuals to stop smoking, to make healthy food choices, to be physically active and, as part of that, to reduce weight and the distribution of weight. The rising tide of obesity in Europe, and elsewhere in the world, is of medical and public health concern. In several European countries, including Finland, the UK, Germany, Hungary, and Belgium, around one-fifth of the adult population are obese [defined by body mass index (BMI).30 kg/m 2 ]. In most countries, obesity prevalence is similar in men and women, with the exception of Turkey where prevalence is considerably higher in women than men. It is not only the current prevalence of obesity that is of concern, but also the time trends in obesity. Between 1981 and 1998, some European countries, including the UK, showed a rapid increase in obesity prevalence, whereas in others, such as Italy and Sweden, obesity prevalence remained at a lower, although not ideal, level. Trends in obesity prevalence in men and women have followed the same direction in the individual countries. There are powerful social, economic, and cultural determinants of obesity in different European populations. This population burden impacts upon our patients. The European Society of Cardiology EUROASPIRE (EUROpean Action on Secondary Prevention through Intervention to Reduce Events) surveys of risk factor management in patients with established coronary heart disease highlight the need for more effective lifestyle intervention. The surveys show considerable potential to reduce risk in patients with established coronary heart disease, because many are not achieving the lifestyle and risk factor goals. EUROASPIRE I was carried out in in nine European countries 5 to assess risk factor management in patients with established coronary heart disease (following acute myocardial infarction or ischaemia, coronary artery bypass surgery, or coronary angioplasty). A second similar survey, EUROASPIRE II, 6 was carried out in in 15 European countries to see whether preventive cardiology had improved since the first survey. In EUROASPIRE I, 3569 patients were interviewed and in EUROASPIRE II, 5556 patients were interviewed. In EUROASPIRE I, 25.3% of patients were obese (BMI 30 kg/m 2 ). In EUROASPIRE II, the prevalence of obesity in these high-risk patients had increased to 32.8%. 7 The increase in obesity was seen across each of the participating countries. Inaddition,inEUROASPIREII,themajorityofpatientswas found to have gained weight following the development of coronary heart disease. 8 Between hospital admission for the index event and interview [carried out at least 6 months (median 1.4 years), after hospital discharge], 24.3% of patients had a weight increase of 5kg (Figure 3).

4 L8 D.A. Wood Figure 3 Distribution of weight changes between time of hospital admission for acute coronary event or procedure and time of interview (6 months after the index event) in EUROASPIRE II. (Adapted with permission from De Bacquer et al. 8 ) The overall prevalence of overweight (BMI kg/m 2 )at the time of interview was 48.2% (51.2% in men and 38.6% in women). Thus, around three-quarters of patients with coronary heart disease were either overweight or obese. Furthermore, 28.1% of patients had abdominal overweight (waist circumference.80 cm in women and.94 cm in men) and 51.7% had abdominal obesity (waist circumference.88 cm in women and.102 cm in men). These data indicate the considerable challenge that we face in terms of lifestyle intervention in patients with coronary heart disease and other atherosclerotic disease, as well as in high-risk individuals in the population. Treatment targets The more successful we are at achieving lifestyle changes, the lower the requirement for antihypertensive and lipid lowering and glucose lowering therapies. The European Guidelines set the following targets in high risk patients for blood pressure and lipid levels:. blood pressure,140/90 mmhg,. total cholesterol,4.5 mmol/l (175 mg/dl),. LDL cholesterol,2.5 mmol/l (100 mg/dl). When these targets are not achieved by lifestyle change, blood pressure lowering and cholesterol lowering drugs should be used. It is important to recognize that lifestyle impacts on the ability to control blood pressure and lipids, despite the use of antihypertensive and lipid lowering therapies. This was demonstrated in the EUROAS- PIRE II analysis. 8 Among patients being treated with lipid lowering agents, 42.7% of normal weight patients were still above the cholesterol target of 5 mmol/l. In contrast, 49.6% of overweight patients and 52.7% of obese patients were still above the target cholesterol level. A similar situation pertained for control of blood pressure in patients taking blood pressure lowering drugs: 42.4% of normal weight patients were still above the blood pressure target of 140/90 mmhg compared with 51.1% of overweight patients and 56.0% of obese patients. The definition of metabolic syndrome in the European Guidelines is the same as that used in the National Cholesterol Education Program. The diagnosis of metabolic syndrome is made when three or more of the following features are present:. waist circumference.102 cm in males and.88 cm in women,. serum triglycerides 1.7 mmol/l (150 mg/dl),. HDL cholesterol,1 mmol/l (,40 mg/dl) in males or,1.3 mmol/l (,50 mg/dl) in females,. blood pressure 130/85 mmhg,. plasma glucose 6.1 mmol/l (110 mg/dl). This is a pragmatic clinical definition. It does not depend on the measurement of insulin, and once again it emphasizes the multi-factorial nature of the causes of atherosclerosis and its complications and the development of diabetes. More recently, a consensus definition developed by the International Diabetes Federation has emphasized the importance of central obesity. 9 Individuals are defined as having a metabolic syndrome if they are centrally obese (defined as waist circumference 94 cm for Europid men and 80 cm for Europid women, with ethnicity specific values for other groups) and have any two of the following four factors:. raised triglyceride level:.150 mg/dl (1.7 mmol/l), or specific treatment for this lipid abnormality;. reduced HDL cholesterol:,40 mg/dl (0.9 mmol/l) in males and,50 mg/dl (1.1 mmol/l) in females, or specific treatment for this lipid abnormality;. raised blood pressure: systolic BP 130 mmhg or diastolic BP 85 mmhg, or treatment of previously diagnosed hypertension;. raised fasting plasma glucose (FPG): 100 mg/dl (5.6 mmol/l), or previously diagnosed Type 2 diabetes. (If.5.6 mmol/l or 100 mg/dl, OGTT is strongly recommended but is not necessary to define the presence of the syndrome.)

5 Guidelines on cardiovascular risk assessment and management L9 For patients with Type 2 diabetes, the treatment goals in the European guidelines include glycaemic targets. In addition, there are clearly defined blood pressure and lipid targets for patients with diabetes, supported by recent evidence from randomized controlled trials (Table 2). It is now clear that in the diabetic population and in patients with impaired glucose regulation, it is as important to address blood pressure and lipids as it is to address the glucose level. The European guidelines have lower blood pressure and lipid targets in patients with Type 2 diabetes than in other patient groups:. blood pressure,130/80 mmhg,. total cholesterol,4.5 mmol/l (,175 mg/dl),. LDL cholesterol,2.5 mmol/l (,100 mg/dl). In terms of other prophylactic medication, there are five different classes of recommended drugs: antiplatelet therapies, beta-blockers, ACE-inhibitors, lipid lowering therapies (principally statins), and anticoagulants. These drugs have all been shown to reduce the risk of all-cause mortality in selected patient populations with established atherosclerotic disease. Aspirin (at least 75 mg) should be considered for all coronary heart disease patients and for those with cerebral atherosclerosis and peripheral atherosclerotic disease. Beta-blockers are recommended following myocardial infarction, and ACE-inhibitors are recommended in patients with symptoms or signs of heart failure at the time of myocardial infarction, or patients with chronic left ventricular dysfunction (ejection fraction,40%). Anticoagulants are recommended in selected patients with coronary heart disease. In healthy high-risk individuals, the armamentarium is more limited because the trial evidence is more limited. Aspirin (75 mg) is recommended in treated hypertensive patients and in men at particularly high risk of coronary heart disease. The lifestyle, risk factor, and therapeutic targets are important to achieve in our patients to reduce the incidence of first or recurrent clinical atherosclerotic events and to reduce the disability associated with cardiovascular disease. The data from INTERHEART 4 can Table 2 Treatment goals in patients with Type 2 diabetes (adapted from De Backer et al. 2 ) Goal HbA1c (DCCT standardized) 6.1 Venous plasma glucose Pre-prandial (fasting) 6.0 mmol/l (,110 mg/dl) Self-monitored blood glucose Pre-prandial (fasting) mmol/l (70 90 mg/dl) Post-prandial mmol/l ( mg/dl) Blood pressure,130/80 mmhg Total cholesterol,4.5 mmol/l (,175 mg/dl) LDL cholesterol,2.5 mmol/l (,100 mg/dl) Figure 4 Reduced risk of acute myocardial infarction associated with not smoking, daily fruit/vegetables, regular physical activity, and moderate alcohol. (Adapted with permission from Yusuf et al. 4 ) be used to assess to what extent the risk of developing myocardial infarction could be reduced if effective lifestyle change is achieved (Figure 4). It shows, for example, that if a person stops smoking, they reduce their risk by about 65%. By not smoking, eating fruit and vegetables, taking exercise, and moderate alcohol consumption, the risk of developing myocardial infarction could be reduced by 81%. Conclusion Implementing preventive strategies based on current scientific knowledge would avert the majority of premature coronary heart disease worldwide. For patients, this would mean both a better quality of life in terms of less disability and also a longer life. The challenge for physicians is to translate this knowledge into effective preventive care. Key points. The priority group for cardiovascular disease prevention is patients with established cardiovascular disease.. In asymptomatic, apparently healthy individuals, preventive strategies should depend on the assessment of the individual s total cardiovascular risk.. The prevalence of overweight and obesity is increasing in patients with coronary heart disease. This has a major impact on cardiovascular risk and can also limit the response to antihypertensive and lipid lowering therapy.. The INTERHEART study has shown that nine modifiable risk factors account for 90% of the population attributable risk of myocardial infarction. Conflict of interest: The author has lectured at Abbott-sponsored symposia.

6 L10 D.A. Wood References 1. European Society of Cardiology. Cardiovascular Diseases in Europe: Euro Heart Survey and National Registries of Cardiovascular Diseases and Patient Management Sophia Antipolis, France: ESC. 2. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10(Suppl. 1):S1 S Conroy RM, Pyorala K, Fitzgerald AP et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24: Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004;364: EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997;18: EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Eur Heart J 2001;22: EUROASPIRE Study Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357: De Bacquer D, De Backer G, Cokkinos D et al. for the EUROASPIRE II study group. Overweight and obesity in patients with established coronary heart disease: are we meeting the challenge? Eur Heart J 2004;25: International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. (14 April 2005).

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating

More information

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV GUY DE BACKER Ghent University,Belgium ESC Congress 2012, aug.25-29th, Munich, Germany ESC Congress 2012, aug.25-29th, Munich,

More information

Models of preventive care in clinical practice to achieve 25 by 25

Models of preventive care in clinical practice to achieve 25 by 25 Models of preventive care in clinical practice to achieve 25 by 25 Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College

More information

The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention

The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention Brief Report The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention Kornelia Kotseva 1,2 ; on behalf of the EUROASPIRE Investigators 1 National Heart & Lung Institute, Imperial College

More information

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO

More information

DECLARATION OF CONFLICT OF INTEREST. None

DECLARATION OF CONFLICT OF INTEREST. None DECLARATION OF CONFLICT OF INTEREST None Dietary changes and its influence on cardiovascular diseases in Asian and European countries Problems of Eastern European countries for cardiovascular disease prevention

More information

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High

More information

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients

More information

Cardiovascular disease - from management to prevention

Cardiovascular disease - from management to prevention Cardiovascular disease - from management to prevention Reflections originating from the Fourth Joint European Societies Task Force on Cardiovascular Disease Prevention in Clinical Practice 2007 WHAT IS

More information

Secondary Prevention of Coronary Heart Disease in Primary Health Care

Secondary Prevention of Coronary Heart Disease in Primary Health Care & Secondary Prevention of Coronary Heart Disease in Primary Health Care Olivera Batić-Mujanović¹*, Muharem Zildžić², Azijada Beganlić¹ 1. House of Health Tuzla, Family Medicine Teaching Center, Albina

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE 2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE Massimo F Piepoli, MD, PhD, FESC, Piacenza, Italy on behalf of the 6 th Joint Task Force 2 3 Guidelines still based upon the principles of

More information

Identification of subjects at high risk for cardiovascular disease

Identification of subjects at high risk for cardiovascular disease Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

the high CVD risk smoker

the high CVD risk smoker Smoking Cessation: population and patients A comprehensive approach to the smoker the high CVD risk smoker Catriona Jennings Cardiovascular Specialist Research Nurse Imperial College London European Society

More information

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary 2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth

More information

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

EUROACTION. A European Society of Cardiology Demonstration Project in Preventive Cardiology FINAL RESULTS

EUROACTION. A European Society of Cardiology Demonstration Project in Preventive Cardiology FINAL RESULTS EUROACTION A European Society of Cardiology Demonstration Project in Preventive Cardiology FINAL RESULTS Professor David Wood on behalf of the EUROACTION Group EUROACTION 8 countries 24 centres 962 subjects

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

Depok-Indonesia STEPS Survey 2003

Depok-Indonesia STEPS Survey 2003 The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural

More information

Type 2 diabetes, the metabolic syndrome and cardiovascular disease in Europe

Type 2 diabetes, the metabolic syndrome and cardiovascular disease in Europe the metabolic syndrome and cardiovascular disease in Europe Diabetes Diabetes mellitus is a chronic disease which has been described as a state of raised blood glucose (hyperglycaemia) associated with

More information

THE CRITICAL ROLE OF NURSES. Helping patients take control of their LDL-C to lower the risk of MI and stroke.

THE CRITICAL ROLE OF NURSES. Helping patients take control of their LDL-C to lower the risk of MI and stroke. THE CRITICAL ROLE OF NURSES Helping patients take control of their LDL-C to lower the risk of MI and stroke. WHEN IT COMES TO REDUCING PATIENTS HIGH CHOLESTEROL, NURSES PLAY A KEY ROLE Many patients may

More information

Metabolic Syndrome.

Metabolic Syndrome. www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present

More information

Clinical Practice Guideline

Clinical Practice Guideline Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

Five chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical

More information

Clinical Recommendations: Patients with Periodontitis

Clinical Recommendations: Patients with Periodontitis The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Professor Norman Sharpe. Heart Foundation West Coast

Professor Norman Sharpe. Heart Foundation West Coast Professor Norman Sharpe Heart Foundation West Coast Primary Care the Keystone to Heart Health Improvement Norman Sharpe June 2013 The heart health continuum and the keystone position The culprit disease

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:

More information

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple

More information

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still

More information

ASSeSSing the risk of fatal cardiovascular disease

ASSeSSing the risk of fatal cardiovascular disease ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril

More information

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:

More information

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia

More information

Understanding the metabolic syndrome

Understanding the metabolic syndrome Understanding the metabolic syndrome Understanding the metabolic system Metabolic syndrome is the clustering together of a number of risk factors for heart disease, stroke and diabetes. Having one of these

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II survey

Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II survey European Heart Journal Supplements (2004) 6 (Supplement J), J17 J26 Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II survey

More information

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012 SAMUEL TCHWENKO, MD, MPH Epidemiologist, Heart Disease & Stroke Prevention Branch Chronic Disease & Injury Section; Division of Public Health NC Department of Health & Human Services JUSTUS WARREN TASK

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator

More information

programme. The DE-PLAN follow up.

programme. The DE-PLAN follow up. What are the long term results and determinants of outcomes in primary health care diabetes prevention programme. The DE-PLAN follow up. Aleksandra Gilis-Januszewska, Noël C Barengo, Jaana Lindström, Ewa

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

Cardiovascular Risk Assessment and Management Making a Difference

Cardiovascular Risk Assessment and Management Making a Difference Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014 Numbers and age-standardised mortality rates from all causes, by sex, 1950 2010 Death rates halved Life expectancy

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM:

REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM: REPORT FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM: PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP,

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute

More information

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke «L Europe de la santé au service des patients» 13-14 October 2008 - Institut Pasteur Paris Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke Simona Giampaoli National Centre of

More information

Cardiovascular Complications in Diabetes

Cardiovascular Complications in Diabetes What is all the fuss about? Cardiovascular Complications in Diabetes Dina Shrestha MD Consultant Endocrinologist Norvic International Hospital and Medical College Hospital for Advanced Medicine and Surgery

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

Risks and benefits of weight loss: challenges to obesity research

Risks and benefits of weight loss: challenges to obesity research European Heart Journal Supplements (2005) 7 (Supplement L), L27 L31 doi:10.1093/eurheartj/sui083 Risks and benefits of weight loss: challenges to obesity research Donna Ryan* Pennington Biomedical Research

More information

2013 Hypertension Measure Group Patient Visit Form

2013 Hypertension Measure Group Patient Visit Form Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part

More information

ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk

ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk CONSIDER YOUR HEART HEALTH: REDUCE YOUR CHOLESTEROL Uncontrolled or continuous high cholesterol

More information

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life

More information

Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight

Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight Quest, Quest Diagnostics, the associated logo, and all associated Quest Diagnostics marks are the registered trademarks of Quest

More information

Diabetes Control and Complications in Public Hospitals in Malaysia

Diabetes Control and Complications in Public Hospitals in Malaysia ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,

More information

Know Your Numbers. Your guide to maintaining good health. Helpful information from Providence Medical Center and Saint John Hospital

Know Your Numbers. Your guide to maintaining good health. Helpful information from Providence Medical Center and Saint John Hospital Know Your Numbers Your guide to maintaining good health Helpful information from Providence Medical Center and Saint John Hospital If it has been awhile since your last check up and you are searching for

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants Aggregate Report Fasting Biometric Screening CLIENTXXXX May 2, 2014 21,000 participants Contact:404.636.9437~Website:www.atlantahealthsys.com RISK FACTOR QUESTIONNAIRE Participants Percent Do not exercise

More information

Methods. OR and PAR both presented with 99% confidence intervals. All analyses adjusted for age, sex and region.

Methods. OR and PAR both presented with 99% confidence intervals. All analyses adjusted for age, sex and region. INTERHEART: Aims 1. To evaluate the association (odds ratio) of risk factors for MI globally, and in each region; and among major ethnic groups in the world. 2. To quantify the impact of each risk factor

More information

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures THE CVD CHALLENGE IN NORTHERN IRELAND Together we can save lives and reduce NHS pressures The challenge of CVD continues today. Around 225,000 people in Northern Ireland live with the burden of cardiovascular

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Population models of health impact of combination polypharmacy

Population models of health impact of combination polypharmacy Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067

More information

A CASE REPORT AND LITERATURE REVIEW ON MYOCARDIAL INFARCTION WITH NORMAL CORONARY ARTERIES

A CASE REPORT AND LITERATURE REVIEW ON MYOCARDIAL INFARCTION WITH NORMAL CORONARY ARTERIES A CASE REPORT AND LITERATURE REVIEW ON MYOCARDIAL INFARCTION WITH NORMAL CORONARY ARTERIES Niyamtullah Musalman 1*, Lijun Jin 2 and Farhan Khan 3 *12 Department of Cardiology, Yangtze Medical University

More information

Practice-Level Executive Summary Report

Practice-Level Executive Summary Report PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular

More information

Statistical Fact Sheet Populations

Statistical Fact Sheet Populations Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total

More information

Prevention in Europe

Prevention in Europe Prevention in Europe Geneviève Derumeaux Créteil University, France Ian M Graham Trinity College, Dublin ESC: 2016 Lipid guidelines 2016 Joint Prevention Guidelines Cardiovascular disease in Europe Nick

More information

EuroPrevent 2010 Fatal versus total events in risk assessment models

EuroPrevent 2010 Fatal versus total events in risk assessment models EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the

More information

Risk factor indicators in offspring of patients with premature coronary heart disease in Banja Luka region/republic of Srpska/Bosnia and Herzegovina

Risk factor indicators in offspring of patients with premature coronary heart disease in Banja Luka region/republic of Srpska/Bosnia and Herzegovina Clinical research Risk factor indicators in offspring of patients with premature coronary heart disease in Banja Luka region/republic of Srpska/Bosnia and Herzegovina Dusko Vulic 1, Sasa Loncar 2, Miodrag

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Strategies for the prevention of type 2 diabetes and cardiovascular disease

Strategies for the prevention of type 2 diabetes and cardiovascular disease European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana

More information

National Strategy. for Control and Prevention of Non - communicable Diseases in Kingdom of Bahrain

National Strategy. for Control and Prevention of Non - communicable Diseases in Kingdom of Bahrain Kingdom of Bahrain Ministry of Health National Strategy for Control and Prevention of Non - communicable Diseases in Kingdom of Bahrain 2014 2025 Behavioural Risk Factors Tobacco Use Unhealthy Diets Physical

More information

Heart Disease Genesis

Heart Disease Genesis Heart Disease Genesis The Ultimate Lecture on CAD origins Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Friends, Romans, Cardiac Practitioners, lend me your ears; I come here to bury LDL, not to praise him

Friends, Romans, Cardiac Practitioners, lend me your ears; I come here to bury LDL, not to praise him Friends, Romans, Cardiac Practitioners, lend me your ears; I come here to bury LDL, not to praise him Adapted from Julius Caesar: Act 3, Scene 2, Page 4 An Alternative Viewpoint A Biomedical Approach to

More information

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered

More information

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti

More information

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of

More information

European Guidelines on CVD Prevention Fourth Joint European Societies Task Force on cardiovascular disease prevention in clinical practice

European Guidelines on CVD Prevention Fourth Joint European Societies Task Force on cardiovascular disease prevention in clinical practice European Guidelines on CVD Prevention Fourth Joint European Societies Task Force on cardiovascular disease prevention in clinical practice September 2007 1 Recent developments in CVD prevention in Europe

More information

290 Biomed Environ Sci, 2016; 29(4):

290 Biomed Environ Sci, 2016; 29(4): 290 Biomed Environ Sci, 2016; 29(4): 290-294 Letter to the Editor Prevalence and Predictors of Hypertension in the Labor Force Population in China: Results from a Cross-sectional Survey in Xinjiang Uygur

More information

Dyslipidemia in women: Who should be treated and how?

Dyslipidemia in women: Who should be treated and how? Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European

More information

DIABETES. A growing problem

DIABETES. A growing problem DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought

More information

Diabetes, Diet and SMI: How can we make a difference?

Diabetes, Diet and SMI: How can we make a difference? Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative

More information

THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY

THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

SCIENTIFIC STUDY REPORT

SCIENTIFIC STUDY REPORT PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established

More information

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information